BB Biotech AG/€BION
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About BB Biotech AG
BB Biotech AG is an investment company that focuses on investments in the biotechnology industry. The company is headquartered in Schaffhausen, Switzerland, and specializes in managing a portfolio primarily composed of companies involved in the development of innovative drugs and therapies. It seeks to capture growth opportunities in the biotech sector by investing in firms with cutting-edge scientific research and promising product pipelines. BB Biotech AG's investment strategy is informed by an in-depth analysis of market trends and scientific advancements, ensuring a dynamic and diversified portfolio. Its geographic footprint is primarily in Europe, with strategic investments in biotech firms globally.
Ticker
€BION
Sector
Primary listing
XGAT
Employees
10
Headquarters
Küsnacht, Switzerland
BB Biotech AG Metrics
BasicAdvanced
€2.5B
13.58
€3.26
0.79
€1.89
4.27%
Price and volume
Market cap
€2.5B
Beta
0.79
52-week high
€45.00
52-week low
€25.97
Average daily volume
9.9K
Dividend rate
€1.89
Financial strength
Current ratio
631.7
Quick ratio
22.4
Dividend payout ratio (TTM)
59.29%
Interest coverage (TTM)
210.18%
Profitability
Gross margin (TTM)
100.00%
Net profit margin (TTM)
82.47%
Operating margin (TTM)
86.72%
Effective tax rate (TTM)
0.03%
Revenue per employee (TTM)
€21,707,490
Management effectiveness
Return on assets (TTM)
4.53%
Return on equity (TTM)
7.32%
Valuation
Price to earnings (TTM)
13.584
Price to revenue (TTM)
11.158
Price to book
0.99
Price to tangible book (TTM)
0.99
Price to free cash flow (TTM)
4.989
Free cash flow yield (TTM)
20.04%
Free cash flow per share (TTM)
8.865
Dividend yield (TTM)
4.27%
Forward dividend yield
4.27%
Growth
Revenue change (TTM)
352.51%
Earnings per share change (TTM)
32.16%
3-year revenue growth (CAGR)
2.47%
10-year revenue growth (CAGR)
-13.98%
3-year earnings per share growth (CAGR)
-42.34%
10-year earnings per share growth (CAGR)
-15.08%
3-year dividend per share growth (CAGR)
-22.39%
10-year dividend per share growth (CAGR)
-2.51%
Bulls say / Bears say
BB Biotech narrowed its portfolio to 23 positions and shifted focus toward mid-cap companies with market capitalizations above USD 1 billion, initiating a new position in Akero Therapeutics following strong Phase II data, which should enhance portfolio quality and resilience (BB Biotech Q1 2025 release).
Several portfolio companies achieved key regulatory milestones in Q1 2025, including FDA approval for Vertex’s JOURNAVX™ and an expanded indication for Alnylam’s Amvuttra, validating BB Biotech’s investment selections and driving long-term growth potential (BB Biotech Q1 2025 release).
In Q2 2025, BB Biotech’s NAV rose 5.8% in USD—beating the Nasdaq Biotechnology Index by 5.9 percentage points—and the share discount to NAV tightened to 10.5%, demonstrating the fund’s ability to outperform amid a stabilizing macro backdrop (BB Biotech Q2 2025 release).
BB Biotech reported a net loss of CHF 241 million in Q1 2025, reversing a CHF 260 million profit in Q1 2024 and underscoring continued valuation headwinds across its portfolio (BB Biotech Q1 2025 release).
BB Biotech incurred a net loss of CHF 100 million in Q2 2025, marking a second consecutive quarterly loss and highlighting sustained pressure on its investment portfolio’s valuations (BB Biotech Q2 2025 release).
BB Biotech shares fell 8.8% in CHF during Q1 2025, compared to a 3.9% decline in the Nasdaq Biotechnology Index, indicating the stock’s relative underperformance amid sector volatility (BB Biotech Q1 2025 release).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BB Biotech AG stock?
BB Biotech AG (BION) has a market cap of €2.5B as of October 31, 2025.
What is the P/E ratio for BB Biotech AG stock?
The price to earnings (P/E) ratio for BB Biotech AG (BION) stock is 13.58 as of October 31, 2025.
Does BB Biotech AG stock pay dividends?
Yes, the BB Biotech AG (BION) stock pays dividends to shareholders. As of October 31, 2025, the dividend rate is €1.88939 and the yield is 4.27%. BB Biotech AG has a payout ratio of 59.29% on a trailing twelve-month basis.
When is the next BB Biotech AG dividend payment date?
The next BB Biotech AG (BION) dividend payment date is unconfirmed.
What is the beta indicator for BB Biotech AG?
BB Biotech AG (BION) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.